株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ウェット型(新生血管型/滲出型)黄斑変性症:パイプライン分析

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 245984
出版日 ページ情報 英文 267 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
ウェット型(新生血管型/滲出型)黄斑変性症:パイプライン分析 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016
出版日: 2016年08月24日 ページ情報: 英文 267 Pages
概要

ウェット型(新生血管型/滲出型)黄斑変性症は、失明をもたらす慢性の眼疾患です。症状は、視覚の歪み、色の強さや明るさの低下、視界の中にぼける部分・欠ける部分がある、突発性が挙げられます。素因として、年齢、喫煙、肥満、高血圧、炎症、心血管疾患などが挙げられます。

当レポートでは、ウェット型(新生血管型/滲出型)黄斑変性症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

ウェット型(新生血管型/滲出型)黄斑変性症の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

治療薬の開発に従事している企業

  • Aciont Inc.
  • Allergan Plc
  • Amakem NV
  • Apellis Pharmaceuticals, Inc.
  • Apexigen, Inc.
  • Applied Genetic Technologies Corporation
  • Avalanche Biotechnologies, Inc.
  • Benitec Biopharma Limited
  • BIOCAD
  • Boehringer Ingelheim GmbH
  • Charlesson LLC.
  • Chong Kun Dang Pharmaceutical Corp.
  • Circadian Technologies Limited
  • Clanotech AB
  • Clearside BioMedical, Inc.
  • Coherus BioSciences, Inc.
  • 第一三共
  • Delenex Therapeutics AG
  • Eleven Biotherapeutics Inc.
  • Exonate Limited
  • F. Hoffmann-La Roche Ltd.
  • Formycon AG
  • GTx, Inc.
  • iCo Therapeutics Inc.
  • Icon Bioscience, Inc.
  • Kala Pharmaceuticals, Inc.
  • Kodiak Sciences, Inc.
  • Mabion SA
  • Mitotech S.A.
  • Neurotech Pharmaceuticals, Inc.
  • Ocular Therapeutix, Inc.
  • Ohr Pharmaceutical Inc.
  • Ophthotech Corp.
  • Oxford BioMedica Plc
  • PanOptica, Inc.
  • Pfenex Inc.
  • Pfizer Inc.
  • pSivida Corp.
  • Quark Pharmaceuticals, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • RegenxBio Inc.
  • RXi Pharmaceuticals Corporation
  • 参天製薬
  • 三和化学研究所
  • TRACON Pharmaceuticals, Inc.
  • TWi Pharmaceuticals, Inc.
  • Tyrogenex, Inc.
  • Xbrane Biopharma AB

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • (アフリベルセプト + nesvacumab)
  • (アフリベルセプト + rinucumab)
  • abicipar pegol
  • AC-301
  • ACX-107
  • アフリベルセプト
  • アフリベルセプトのバイオシミラー
  • AGN-151200
  • ALG-1001
  • AMA-0428
  • APL-2
  • APX-003
  • APX-3330
  • AVA-101
  • AVA-201
  • avacincaptad pegol sodium
  • AXT-108
  • bertilimumab
  • Beta-LGND2
  • ベバシズマブのバイオシミラー
  • BI-144807
  • brolucizumab
  • C-16Y
  • CLT-005
  • CLT-28643
  • cyclosporine
  • DE-120
  • DLX-1008
  • DNX-214
  • Doxarubicin Pegylated
  • 加齢性黄斑変性症(AMD)治療薬
  • ウェット型 AMD・ドライ型 AMD 治療薬
  • DS-7080
  • ENV-1305
  • ENV-705
  • GB-101
  • GB-102
  • ウェット型AMD 向け遺伝子療法
  • K-106
  • KSI-201
  • LHA-510
  • LMG-324
  • ウェット型AMD 向け VEGF 阻害モノクローナル抗体
  • nesvacumab
  • NT-503
  • NT-506
  • OCU-200
  • OLX-301
  • ONL-1204
  • OXB-201
  • PAN-90806
  • pegpleranib sodium
  • PF-05206388
  • PF-655
  • plastoquinone decyl triphenylphosphonium bromide
  • ウェット型AMD 向け VEGF阻害タンパク質
  • ラニビズマブ
  • ラニビズマブのバイオシミラー
  • 加齢性黄斑変性症向け組換型タンパク質
  • ウェット型AMD 向け VEGF 阻害組換型タンパク質
  • RG-7716
  • RGX-314
  • RXI-109
  • SK-1011
  • ウェット/ドライ型 AMD向け小分子
  • ウェット型AMD 向け VEGF/PDGF阻害小分子
  • SPHINX-31
  • squalamine lactate
  • ウェット型AMD向け VEGF阻害合成ペプチド
  • TRC-105
  • トリアムシノロン・アセトニド
  • TT-211
  • TT-231
  • VGX-300
  • X-82

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8376IDB

Summary

Global Markets Direct's, 'Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016', provides an overview of the Wet (Neovascular / Exudative) Macular Degeneration pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Wet (Neovascular / Exudative) Macular Degeneration
  • The report reviews pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Wet (Neovascular / Exudative) Macular Degeneration therapeutics and enlists all their major and minor projects
  • The report assesses Wet (Neovascular / Exudative) Macular Degeneration therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Wet (Neovascular / Exudative) Macular Degeneration Overview
  • Therapeutics Development
    • Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview
  • Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies
  • Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development
    • Aciont Inc.
    • Adverum Biotechnologies, Inc.
    • Allergan Plc
    • Alteogen Inc.
    • Amakem NV
    • Ampio Pharmaceuticals, Inc.
    • Apellis Pharmaceuticals, Inc.
    • Apexigen, Inc.
    • Applied Genetic Technologies Corporation
    • Benitec Biopharma Limited
    • Boehringer Ingelheim GmbH
    • Cell Medica Limited
    • Charlesson LLC.
    • Cipla Ltd.
    • Clanotech AB
    • Clearside BioMedical, Inc.
    • Clonz Biotech Private Limited
    • Coherus BioSciences, Inc.
    • Daiichi Sankyo Company, Limited
    • Diffusion Pharmaceuticals Inc.
    • Eleven Biotherapeutics Inc.
    • Exonate Limited
    • F. Hoffmann-La Roche Ltd.
    • Formycon AG
    • Graybug Vision Inc
    • GTx, Inc.
    • iCo Therapeutics Inc.
    • Icon Bioscience, Inc.
    • Iconic Therapeutics, Inc.
    • Kala Pharmaceuticals, Inc.
    • Kodiak Sciences Inc.
    • Mabion SA
    • MeiraGTx Limited
    • Mitotech S.A.
    • Ocular Therapeutix, Inc.
    • Ohr Pharmaceutical Inc.
    • Ophthotech Corp.
    • Oxford BioMedica Plc
    • PanOptica, Inc.
    • Pfenex Inc.
    • Pfizer Inc.
    • pSivida Corp.
    • Regeneron Pharmaceuticals Inc
    • RegenxBio Inc.
    • RXi Pharmaceuticals Corporation
    • Santen Pharmaceutical Co., Ltd.
    • Sanwa Kagaku Kenkyusho Co., Ltd.
    • TRACON Pharmaceuticals, Inc.
    • TWi Pharmaceuticals, Inc.
    • Tyrogenex, Inc.
    • Xbrane Biopharma AB
  • Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (aflibercept + nesvacumab) - Drug Profile
    • (aflibercept + rinucumab) - Drug Profile
    • A-006 - Drug Profile
    • abicipar pegol - Drug Profile
    • AC-301 - Drug Profile
    • ACX-107 - Drug Profile
    • aflibercept - Drug Profile
    • aflibercept biosimilar - Drug Profile
    • aflibercept biosimilar - Drug Profile
    • AGN-151200 - Drug Profile
    • ALG-1001 - Drug Profile
    • AMA-0428 - Drug Profile
    • APL-2 - Drug Profile
    • APX-003 - Drug Profile
    • APX-3330 - Drug Profile
    • AVA-101 - Drug Profile
    • AVA-201 - Drug Profile
    • avacincaptad pegol sodium - Drug Profile
    • axitinib - Drug Profile
    • AXT-108 - Drug Profile
    • bertilimumab - Drug Profile
    • Beta-LGND2 - Drug Profile
    • BI-144807 - Drug Profile
    • brolucizumab - Drug Profile
    • C-16Y - Drug Profile
    • CBT-128 - Drug Profile
    • CLT-005 - Drug Profile
    • CLT-28643 - Drug Profile
    • cyclosporine - Drug Profile
    • DA-3131 - Drug Profile
    • danazol - Drug Profile
    • DE-120 - Drug Profile
    • DNX-214 - Drug Profile
    • Doxarubicin Pegylated - Drug Profile
    • Drug for Age Related Macular Degeneration - Drug Profile
    • DS-7080 - Drug Profile
    • ENV-1305 - Drug Profile
    • GB-101 - Drug Profile
    • Gene Therapy 1 for Wet Age-Related Macular Degeneration - Drug Profile
    • Gene Therapy for Wet Age-related Macular Degeneration - Drug Profile
    • hI-con1 - Drug Profile
    • IVMED-50 - Drug Profile
    • IVMED-55 - Drug Profile
    • K-106 - Drug Profile
    • KSI-201 - Drug Profile
    • LHA-510 - Drug Profile
    • Monoclonal Antibody to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile
    • OCU-200 - Drug Profile
    • OLX-301 - Drug Profile
    • ONL-1204 - Drug Profile
    • OPT-302 - Drug Profile
    • OXB-201 - Drug Profile
    • PAN-90806 - Drug Profile
    • pegpleranib sodium - Drug Profile
    • PF-05206388 - Drug Profile
    • PF-655 - Drug Profile
    • plastoquinone decyl triphenylphosphonium bromide - Drug Profile
    • Protein to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile
    • ranibizumab - Drug Profile
    • ranibizumab biosimilar - Drug Profile
    • ranibizumab biosimilar - Drug Profile
    • ranibizumab biosimilar - Drug Profile
    • ranibizumab biosimilar - Drug Profile
    • ranibizumab biosimilar - Drug Profile
    • ranibizumab biosimilar - Drug Profile
    • ranibizumab biosimilar - Drug Profile
    • Recombinant Protein for Age Related Macular Degeneration - Drug Profile
    • Recombinant Proteins to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile
    • RES-529 - Drug Profile
    • RG-7716 - Drug Profile
    • RGX-314 - Drug Profile
    • RXI-109 - Drug Profile
    • SK-1011 - Drug Profile
    • Small Molecule for Wet AMD and Dry AMD - Drug Profile
    • Small Molecules for Dry and Wet Age Related Macular Degeneration - Drug Profile
    • Small Molecules to Inhibit SRPK-1 for Wet Macular Degeneration - Drug Profile
    • SPHINX-31 - Drug Profile
    • squalamine lactate - Drug Profile
    • sunitinib malate - Drug Profile
    • Synthetic Peptides to Inhibit VEGF for Wet Adult Macular Degeneration - Drug Profile
    • TRC-105 - Drug Profile
    • triamcinolone acetonide - Drug Profile
    • TT-211 - Drug Profile
    • TT-231 - Drug Profile
    • X-82 - Drug Profile
  • Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects
  • Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products
  • Wet (Neovascular / Exudative) Macular Degeneration - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Aciont Inc., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Adverum Biotechnologies, Inc., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Allergan Plc, H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Alteogen Inc., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Amakem NV, H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Apellis Pharmaceuticals, Inc., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Apexigen, Inc., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Applied Genetic Technologies Corporation, H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Benitec Biopharma Limited, H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Cell Medica Limited, H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Charlesson LLC., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Cipla Ltd., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Clanotech AB, H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Clearside BioMedical, Inc., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Clonz Biotech Private Limited, H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Coherus BioSciences, Inc., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Diffusion Pharmaceuticals Inc., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Eleven Biotherapeutics Inc., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Exonate Limited, H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Formycon AG, H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Graybug Vision Inc, H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by GTx, Inc., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by iCo Therapeutics Inc., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Icon Bioscience, Inc., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Iconic Therapeutics, Inc., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Kala Pharmaceuticals, Inc., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Kodiak Sciences Inc., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Mabion SA, H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by MeiraGTx Limited, H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Mitotech S.A., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ocular Therapeutix, Inc., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ohr Pharmaceutical Inc., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ophthotech Corp., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Oxford BioMedica Plc, H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by PanOptica, Inc., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Pfenex Inc., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Pfizer Inc., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by pSivida Corp., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by RegenxBio Inc., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by RXi Pharmaceuticals Corporation, H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by TRACON Pharmaceuticals, Inc., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by TWi Pharmaceuticals, Inc., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Tyrogenex, Inc., H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Xbrane Biopharma AB, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects, H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects (Contd..1), H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects (Contd..2), H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects (Contd..3), H2 2016
  • Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top